Applied Therapeutics Inc APLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APLT is a good fit for your portfolio.
News
-
Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review
-
FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment
-
Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round
-
Applied Therapeutics Shares Hit 52-Week High on Govorestat Filings
-
Applied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDA
Trading Information
- Previous Close Price
- $4.31
- Day Range
- $4.17–4.36
- 52-Week Range
- $1.09–9.39
- Bid/Ask
- $4.24 / $5.20
- Market Cap
- $483.24 Mil
- Volume/Avg
- 568,591 / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 36.33
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
Comparables
Valuation
|
Metric
|
APLT
|
ITOS
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.66 | 0.69 |
Price/Sales | 36.33 | 30.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
APLT
ITOS
SLRN
Financial Strength
|
Metric
|
APLT
|
ITOS
|
SLRN
|
|---|---|---|---|
Quick Ratio | 0.70 | 13.46 | 8.53 |
Current Ratio | 0.76 | 13.76 | 8.65 |
Interest Coverage | — | — | — |
Quick Ratio
APLT
ITOS
SLRN
Profitability
|
Metric
|
APLT
|
ITOS
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −131.65% | −12.92% | −57.50% |
Return on Equity (Normalized) | — | −14.67% | −88.66% |
Return on Invested Capital (Normalized) | — | −18.54% | −96.26% |
Return on Assets
APLT
ITOS
SLRN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sqwrpydt | Qxdwy | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Drnvsbfx | Qjthtdm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mlxwmncph | Xmqwh | $99.5 Bil | |
MRNA
| Moderna Inc | Kkcpkdjy | Gwwyw | $38.8 Bil | |
ARGX
| argenx SE ADR | Dtlfxpv | Xstn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mqzqltn | Mxpf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xsyjnybzr | Rpbzfr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yllwtsmnt | Lnjnflf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wmhtnxpb | Tlzjjyx | $12.5 Bil | |
INCY
| Incyte Corp | Yygthqbv | Ztmpt | $11.6 Bil |